State Of Wyoming Castle Biosciences Inc Transaction History

State Of Wyoming

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	BUY	$12.19 - $22.43 $1,414 - $2,601	116 Added 14.25%	930 $20,000
Q3 2023 Nov 14, 2023	BUY	$13.28 - $20.3 $3,824 - $5,846	288 Added 54.75%	814 $13,000
Q2 2023 Aug 14, 2023	BUY	$11.66 - $26.0 $1,504 - $3,354	129 Added 32.49%	526 $7,000
Q1 2023 May 12, 2023	BUY	$19.47 - $28.49 $214 - $313	11 Added 2.85%	397 $9,000
Q4 2022 Feb 14, 2023	SELL	$18.08 - $30.0 $36 - $60	-2 Reduced 0.52%	386 $9,000

Q3 2022 Nov 14, 2022	SELL	$22.51 - $34.32 $337 - $514	-15 Reduced 3.72%	388 $10,000
Q2 2022 Aug 15, 2022	SELL	$16.0 - $45.99 $5,904 - $16,970	-369 Reduced 47.8%	403 $9,000
Q1 2022 May 13, 2022	BUY	$33.17 - $46.98 $6,833 - $9,677	206 Added 36.4%	772 $35,000
Q4 2021 Feb 11, 2022	SELL	$39.06 - $67.58 $703 - $1,216	-18 Reduced 3.08%	566 $24,000
Q3 2021 Feb 11, 2022	BUY	$60.13 - $77.6 $14,551 - $18,779	242 Added 70.76%	584 $39,000
Q2 2021 Feb 11, 2022	BUY	$50.07 - $76.78 $17,123 - $26,258	342 New	342 $25,000

162

25.3M

82.2K

150K

Ticker CSTL
Exchange NASDAQ
Sector Healthcare
Industry Diagnostics & Research
Shares Outstandng 26,297,000
Market Cap $559M
Description
Castle Biosciences, Inc., a commercial-stage diagnostics company, focuses to provide diagnostic and prognostic testing services for dermatological cancers. Its lead product is DecisionDx-Melanoma, a multi-gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma. The company als...

Get notified when there are updates to the investment portfolio of State Of Wyoming, based on Form 13F filings with the SEC.

Stay updated on State Of Wyoming with notifications on news.